Absorbed dose and related quantities are the key predictors of the beneficial (therapeutic) effects of radiation and of the risk and/or severity of its adverse effects. The estimation of such dosimetric parameters is challenging, however, particularly for radiopharmaceuticals.
Richly illustrated and thoroughly referenced, the MIRD Primer 2022: A Complete Guide to Radiopharmaceutical Dosimetry is a comprehensive, state-of-the-art guide to radiopharmaceutical dosimetry that reflects the dramatic evolution of the field of nuclear medicine, including molecular imaging and, increasingly, radiopharmaceutical therapy.
The MIRD Primer 2022 serves as
The historical development of internal dosimetry, uncertainty in dose and radiation risk estimation, currently available dosimetry software, and regulatory aspects of radiopharmaceutical dosimetry are all addressed as well.
Exhaustively revised and greatly expanded from the original MIRD Primer, this book addresses the important distinction between dosimetry for risk assessment in diagnostic imaging versus dosimetry for treatment efficacy and toxicity evaluation in the setting of therapy, including guidance on treatment planning.
Release Date: November 2022 | 298 pages; includes index
Non-Member Price: $154.00
Member Price: $109.00
Rachel M. Bartlett, Wesley E. Bolch, A. Bertrand Brill, Yuni K. Dewaraja, Frederic H. Fahey, Darrell R. Fisher, Robert F. Hobbs, Roger W. Howell, Ruby F. Meredith, Joseph G. Rajendran, George Sgouros (Immediate Past Chairman), Pat Zanzonico (Chairman)